Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastomaRobert S. McNeill, C. Ryan Miller, David Irvin et al.|Neuro-Oncology|2017Cited by 63
Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancerAmanda E.D. Van Swearingen, Carey K. Anders, Maria J. Sambade et al.|Neuro-Oncology|2017Cited by 42